<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964271</url>
  </required_header>
  <id_info>
    <org_study_id>TET-21-002</org_study_id>
    <nct_id>NCT04964271</nct_id>
  </id_info>
  <brief_title>Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants</brief_title>
  <official_title>Identification and Characterization of Commercial RUO Antibodies for the Detection of Specific Prostate Cancer Tumoral Markers Expressed in Potential Circulating Tumoral Cells (CTCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tethis S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tethis S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory research study with the aim of identifying specific cancer biomarkers&#xD;
      in various subtypes of prostate cancer. Blood samples will be collected from 60 participants&#xD;
      divided into 40 patients and 20 healthy donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this research study different commercial RUO (Research Use Only) antibodies will be&#xD;
      purchased and then tested on blood samples obtained by patients affected by prostate cancer&#xD;
      and by healthy participants as control. Sixty participants will be enrolled belonging to&#xD;
      different risk categories:20 participants affected by prostate cancer at low risk, 20&#xD;
      participants affected by prostate cancer at high risk, and 20 participants without a cancer&#xD;
      disease (healthy volunteers) as control.&#xD;
&#xD;
      Risk categorization is based on the definition of the European Association of Urology. After&#xD;
      signing the informed consent form, participants will be screened to evaluate if they meet the&#xD;
      eligibility criteria. If all the criteria are met, participants will be enrolled into the&#xD;
      study and will be asked to provide some demographic and other data. A 13 ml blood sample will&#xD;
      be collected by the participants and shipped to Sponsor's laboratories, in order to be&#xD;
      processed and analysed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of commercial Antibodies capable of identify specific Prostate Cancer Biomarkers</measure>
    <time_frame>day 1 : blood collection day</time_frame>
    <description>Qualitative assessment of Staining Positivity for different Prostate Cancer Biomarkers</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Low risk prostate cancer patients</arm_group_label>
    <description>Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) &lt;10 ng/ml, and stage T1/T2a and Gleason score 3+3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk prostate cancer patients</arm_group_label>
    <description>Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) &gt;20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donor</arm_group_label>
    <description>Participants who are in good health and without history of cancer disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected from among the people who visit the urology department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give and sign a written informed consent for&#xD;
             participation in the study&#xD;
&#xD;
          -  Male, aged 18 years or above&#xD;
&#xD;
          -  Diagnosed with prostate cancer at low or high risk&#xD;
&#xD;
          -  Candidate to active surveillance (in case of low-risk disease) or treatment with&#xD;
             curative intent such as radical prostatectomy or radiation therapy (in case of low&#xD;
             risk patients not willing to undergo active surveillance or patients with high risk&#xD;
             disease)&#xD;
&#xD;
          -  Healthy participants undergoing a visit at the site for reason other than cancer&#xD;
             diagnosis (including prostate cancer)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancies other than prostate cancer (for healthy participants&#xD;
             includes also prostate cancer)&#xD;
&#xD;
          -  Undergone surgery or treatment for prostate cancer before enrolment&#xD;
&#xD;
          -  Presence of known severe coagulation or haematological disorder&#xD;
&#xD;
          -  Absence of written signed informed consent for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Briganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vito Cucchiara, MD</last_name>
    <phone>+390226436923</phone>
    <email>cucchiara.vito@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Briganti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vito Cucchiara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hench IB, Hench J, Tolnay M. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front Med (Lausanne). 2018 Jan 30;5:9. doi: 10.3389/fmed.2018.00009. eCollection 2018. Review.</citation>
    <PMID>29441349</PMID>
  </reference>
  <reference>
    <citation>Rawal S, Yang YP, Cote R, Agarwal A. Identification and Quantitation of Circulating Tumor Cells. Annu Rev Anal Chem (Palo Alto Calif). 2017 Jun 12;10(1):321-343. doi: 10.1146/annurev-anchem-061516-045405. Epub 2017 Mar 6. Review.</citation>
    <PMID>28301753</PMID>
  </reference>
  <reference>
    <citation>Carbone R, Marangi I, Zanardi A, Giorgetti L, Chierici E, Berlanda G, Podest√† A, Fiorentini F, Bongiorno G, Piseri P, Pelicci PG, Milani P. Biocompatibility of cluster-assembled nanostructured TiO2 with primary and cancer cells. Biomaterials. 2006 Jun;27(17):3221-9. Epub 2006 Feb 28.</citation>
    <PMID>16504283</PMID>
  </reference>
  <reference>
    <citation>Zanardi A, Bandiera D, Bertolini F, Corsini CA, Gregato G, Milani P, Barborini E, Carbone R. Miniaturized FISH for screening of onco-hematological malignancies. Biotechniques. 2010 Jul;49(1):497-504. doi: 10.2144/000113445.</citation>
    <PMID>20615202</PMID>
  </reference>
  <reference>
    <citation>Krol I, Schwab FD, Carbone R, Ritter M, Picocci S, De Marni ML, Stepien G, Franchi GM, Zanardi A, Rissoglio MD, Covelli A, Guidi G, Scarinci D, Castro-Giner F, Mazzarella L, Doglioni C, Borghi F, Milani P, Kurzeder C, Weber WP, Aceto N. Detection of clustered circulating tumour cells in early breast cancer. Br J Cancer. 2021 Jul;125(1):23-27. doi: 10.1038/s41416-021-01327-8. Epub 2021 Mar 24.</citation>
    <PMID>33762721</PMID>
  </reference>
  <reference>
    <citation>Scher HI, Graf RP, Schreiber NA, McLaughlin B, Jendrisak A, Wang Y, Lee J, Greene S, Krupa R, Lu D, Bamford P, Louw JE, Dugan L, Vargas HA, Fleisher M, Landers M, Heller G, Dittamore R. Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Res. 2017 Oct 15;77(20):5687-5698. doi: 10.1158/0008-5472.CAN-17-1353. Epub 2017 Aug 17.</citation>
    <PMID>28819021</PMID>
  </reference>
  <reference>
    <citation>Xu L, Jia S, Li H, Yu Y, Liu G, Wu Y, Liu X, Liu C, Zhou Y, Zhang Z, Sheng Y. Characterization of circulating tumor cells in newly diagnosed breast cancer. Oncol Lett. 2018 Feb;15(2):2522-2528. doi: 10.3892/ol.2017.7540. Epub 2017 Dec 6.</citation>
    <PMID>29434968</PMID>
  </reference>
  <reference>
    <citation>Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D. Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer. Onco Targets Ther. 2017 Jul 31;10:3811-3815. doi: 10.2147/OTT.S143020. eCollection 2017.</citation>
    <PMID>28814879</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer biomarker</keyword>
  <keyword>circulating tumoral cell</keyword>
  <keyword>immunofluorescence assay</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a basic research study without an IPD information sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

